Browse studies

Find your next paid study

55 recruiting studies matching your filters

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, eso…

Gastrointestinal CancerColon CancerRectal Cancer+7 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Case Comprehensive Cancer CenterNCT06263088

Phase 1

Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer

This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in live…

Hepatocellular CarcinomaGastrointestinal Cancer MetastaticNeuroendocrine Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Teclison Ltd.NCT02174549

Phase 1

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and effica…

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Phase 2

NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours

This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with…

Metastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05773274

Phase 2

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatm…

Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of IowaNCT06395402

Phase 2

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroe…

Metastatic Malignant Neoplasm in the LiverPancreatic Neuroendocrine TumorStage I Pancreatic Neuroendocrine Tumor AJCC v8+2 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

SWOG Cancer Research NetworkNCT05040360

Observational

Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social functio…

Cancer PainVisceral PainGastrointestinal Neoplasms+76 more

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimen…

Pancreatic CancerThyroid CancerLung Cancer+47 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Phase 3

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LA…

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT06784752

Phase 1

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate p…

GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

RayzeBio, Inc.NCT07165132

Phase 1

211At-MABG in Adults With Advanced Neuroendocrine Cancers

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced b…

PheochromocytomaParagangliomaNeuroendocrine Tumors+3 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of PennsylvaniaNCT07661420

Phase 3

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical ben…

CancerRenal Cell Carcinoma (RCC)Pancreatic Neuroendocrine Tumors (pNET)+6 more

Estimated

~$50 – $2,250

Actual pay is set by the research site.

ExelixisNCT07620574